Slideshow

Albiglutide Effective in Triple Therapy for Uncontrolled Type 2 Diabetes

In obese patients with type 2 diabetes uncontrolled by lifestyle and two oral agents, albiglutide significantly lowered A1c as part of 3-drug therapy.

HARMONY is the global phase 3 clinical trial program for albiglutide (Tanzeum), a GLP-1 receptor agonist administered once weekly by injection. HARMONY 5 evaluated the efficacy and tolerability of albiglutide in obese patients with type 2 diabetes uncontrolled on lifestyle measures and 2 oral medications. Highlights and results in the 8 slides above.

Related Videos
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
© 2024 MJH Life Sciences

All rights reserved.